Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cyclophosphamide
Doxorubicin
/ adverse effects
Etoposide
Fluorodeoxyglucose F18
/ therapeutic use
Hodgkin Disease
/ diagnostic imaging
Humans
Lymphoma, Large B-Cell, Diffuse
/ diagnostic imaging
Neoplasm Staging
Polyethylene Glycols
Prednisone
Rituximab
Vincristine
/ adverse effects
DLBCL
R-COMP and MBVD
c-HL
high-dose non-pegylated liposomal doxorubicin
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
24
06
2022
received:
04
04
2022
accepted:
25
06
2022
pubmed:
13
7
2022
medline:
24
8
2022
entrez:
12
7
2022
Statut:
ppublish
Résumé
We evaluated the impact of liposomal doxorubicin (NPLD) supercharge-containing therapy on interim fluorodeoxyglucose positron emission tomography (interim-FDG-PET) responses in high-risk diffuse large B-cell lymphoma (DLBCL) or classical Hodgkin lymphoma (c-HL). In this phase II study (2016-2021), 81 adult patients with advanced-stage DLBCL (n = 53) and c-HL (n = 28) received front-line treatment with R-COMP-dose-intensified (DI) and MBVD-DI. R-COMP-DI consisted of 70 mg/m
Identifiants
pubmed: 35819919
doi: 10.1111/bjh.18348
pmc: PMC9541306
doi:
Substances chimiques
liposomal doxorubicin
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Polyethylene Glycols
3WJQ0SDW1A
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Etoposide
6PLQ3CP4P3
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
847-860Informations de copyright
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Lancet Oncol. 2017 Aug;18(8):1076-1088
pubmed: 28668386
Control Clin Trials. 1989 Mar;10(1):1-10
pubmed: 2702835
J Clin Oncol. 2012 Sep 20;30(27):3383-8
pubmed: 22869887
Lancet. 2018 Dec 23;390(10114):2790-2802
pubmed: 29061295
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
N Engl J Med. 2022 Jan 27;386(4):351-363
pubmed: 34904799
Anal Cell Pathol (Amst). 2019 Dec 16;2019:8586354
pubmed: 31934533
Cell Immunol. 2018 Aug;330:91-96
pubmed: 29458975
Lancet Haematol. 2020 Nov;7(11):e838-e850
pubmed: 33091357
Leuk Lymphoma. 2019 Dec;60(12):2890-2898
pubmed: 31282794
J Clin Oncol. 2016 Apr 20;34(12):1376-85
pubmed: 26884559
Br J Cancer. 2013 Nov 12;109(10):2560-5
pubmed: 24136151
Ann Oncol. 2011 Mar;22(3):671-680
pubmed: 20693297
J Bone Miner Res. 2015 Dec;30(12):2140-9
pubmed: 26531055
Lancet Haematol. 2021 Jan;8(1):e80-e93
pubmed: 33357487
Ann Hematol. 2017 Apr;96(4):627-637
pubmed: 28130574
Br J Haematol. 2015 Nov;171(4):662-5
pubmed: 25873239
Int J Pharm. 2017 Mar 15;519(1-2):1-10
pubmed: 28063903
Br J Haematol. 2014 Jul;166(1):118-29
pubmed: 24673727
J Clin Oncol. 2010 Apr 10;28(11):1896-903
pubmed: 20212248
Blood Rev. 1998 Mar;12(1):52-71
pubmed: 9597198
Blood. 2018 Apr 12;131(15):1654-1665
pubmed: 29500175
Crit Rev Oncol Hematol. 2021 Jul;163:103377
pubmed: 34087342
Oncologist. 2017 Apr;22(4):422-431
pubmed: 28275118
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
Cancer Res. 1993 Jun 15;53(12):2796-802
pubmed: 8504422
Lancet Haematol. 2021 Jun;8(6):e410-e421
pubmed: 34048680
Br J Haematol. 2022 Sep;198(5):847-860
pubmed: 35819919
Leuk Lymphoma. 2007 Sep;48(9):1721-7
pubmed: 17786707
J Clin Oncol. 2004 Sep 15;22(18):3733-40
pubmed: 15365070
N Engl J Med. 2011 Jul 21;365(3):203-12
pubmed: 21774708
Neoplasia. 2013 Mar;15(3):231-8
pubmed: 23479502
Blood. 2020 Jun 4;135(23):2041-2048
pubmed: 32232482
Antioxid Redox Signal. 2019 Nov 20;31(15):1166-1174
pubmed: 31436110
Eur J Cancer. 2020 Jun;132:85-97
pubmed: 32334339
J Natl Compr Canc Netw. 2022 Apr;20(4):322-334
pubmed: 35390768
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
J Clin Oncol. 1987 Jan;5(1):27-37
pubmed: 2433409
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Int J Mol Sci. 2020 Mar 18;21(6):
pubmed: 32197371
J Natl Compr Canc Netw. 2022 Mar;20(3):285-308
pubmed: 35276674
Breast. 2009 Aug;18(4):218-24
pubmed: 19656681
Cancer Treat Rev. 2019 Jul;77:44-56
pubmed: 31260900
BMC Cancer. 2020 Oct 13;20(1):992
pubmed: 33050897
Nat Commun. 2015 Oct 27;6:8692
pubmed: 26503691
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182